Summary
The antiproteinuric effect of the antiplatelet agent dipyridamole has been assessed after inhibiton of thromboxane B2 (TxB2) synthesis in 8 patients with confirmed membranous glomerulonephritis.
There were three study periods, each of 30 days, and 45 days apart, namely a washout period, treatment with dipyridamole 300 mg/d, and dipyridamole 225 mg/d plus aspirin 150 mg/d. On Days 1 and 30 of each study period serum and urine creatinine, 24-h excretion of protein, creatinine clearance, platelet aggregometry on whole blood and serum TxB2 were measured.
Treatment with dipyridamole alone or with aspirin produced significant inhibition of platelet aggregation and a fall in 24-h protein excretion; the latter amounted to 54% with dipyridamole alone and 56 % with dipyridamole plus aspirin (NS). Dipyridamole plus aspirin caused an 82 % reduction in serum TxB2.
This is a preview of subscription content, log in via an institution to check access.
References
Andrassy K, Ritz E, Mauerhoff T, Bommer J (1982) What is the evidence for activated coagulation in glomerulonephritis? Am J Nephrol 2: 293–294
Andreoli SP, McAteer JA, Mallett C (1990) Reactive oxygen molecule-mediated injury in endothelial and renal tubular epithelial cells in vitro. Kidney Int 38: 785–794
Bellido I, De La Cruz JP, Sánchez de la Cuesta F (1991) RA-642: a potent inhibitor of ferrous-induced lipid peroxidation in cell membranes. Methods Find Exp Clin Pharmacol 13: 371–375
Cámara S, De La Cruz JP, Frutos MA, Sánchez P, Lopez de Novales E, Sánchez E, Sánchez de la Cuesta F (1991) Effects of dipyridamole on the short-term evolution of glomerulonephritis. Nephron 58: 13–16
Cameron JS (1983) Coagulation et complications tromboemboliques au cours du syndrome nephrotique. In: Hamburger J, Crosnier J (eds) Actualités Nephrologiques du l'Hospital Necker. Flammarion, Paris, pp 137–173
Cardinal DC, Flower RJ (1980) The electronic aggregometer: a novel device for assessing platelet behaviour in blood. J Pharmacol Methods 3: 135–158
Clark WF, Friesen M, Linton AL, Lindsay RM (1976) The platelet as a mediator of tissue damage in immune complex glomerulonephritis. Clin Nephrol 6: 287–289
De La Cruz JP, Sintas A, Moreno A García J, Sánchez de la Cuesta F (1991) Dipyridamole and RA-642 inhibit the production of superoxide anion and free radical damage to rat lens. Pharmacol Toxicol 69: 201–204
Fligiel SEG, Ward PA, Johnson KJ, Till GO (1984) Evidence for a role of hydroxyl radical in immune-complex-induced vasculitis. Am J Pathol 115: 375–382
Granström E, Kindahl H, Samuelsson B (1976) Radioimmunoassay for thromboxane B2. Anal Lett 9: 611–627
George C, Clark WF, Cameron JS (1975) The role of platelet in glomerulonephritis. Adv Nephrol 5: 19–65
Iuliano L, Violi F, Ghiselli A, Alessandri C, Balsano F (1989) Dipyridamole inhibits lipid peroxidation and scavenges oxygen radicals. Lipids 24: 430–433
Lianos EA, Andres GA, Dunn MJ (1983) Glomerular prostaglandin and thromboxane synthesis in rat nephrotoxic serum nephritis. Effects on renal hemodynamics. J Clin Invest 72: 1439–1448
Salem HH, Whitworth JA, Koutts J, Kincaid-Smith PS, Firkin BG (1981) Hypercoagulation in glomerulonephritis. Br Med J 282: 2083–2085
Sraer JD, Kanfer A, Rondeau E, Lacave R (1987) Role de l'hémostase dans la physiologie et la physiopathologie glomérulaire. In: Hamburger J, Crosnier J (eds) Actualités Nephrologiques du l'Hospital Necker. Flammarion, Paris, pp 29–56
Yamabe H, Sugawara N, Ozawa K, Kubota H, Fukushi K, Kikuchi K, Onodera K (1984) Glomerular deposition of Hageman factor in IgA nephropathy. Nephron 37: 62–63
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
De La Cruz, J.P., Cámara, S., Frutos, M.A. et al. Effect of dipyridamole with or without aspirin on urine protein excretion in patients with membranous glomerulonephritis. Eur J Clin Pharmacol 43, 307–309 (1992). https://doi.org/10.1007/BF02333029
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02333029